Overview
Trevogrumab (Regeneron) is a research-grade peptide compound that has attracted significant attention in the scientific community for its role in bioactive optimization. Anti-myostatin monoclonal antibody developed by Regeneron. Studied for inhibition of GDF-8 signaling to promote myocyte differentiation and modulate skeletal muscle pathway activity.
This compound belongs to the bioactive category of research peptides and has been the subject of numerous preclinical investigations. Its unique molecular properties make it a valuable tool for researchers exploring novel therapeutic pathways.
Trevogrumab is a fully human IgG4 monoclonal antibody that binds and neutralizes myostatin (GDF-8), a TGF-β superfamily member that negatively regulates skeletal myocyte differentiation. By blocking myostatin from binding its receptor ActRIIB, trevogrumab removes the endogenous brake on myocyte protein synthesis, enabling increased myofiber size and number. Preclinical and clinical studies have explored its potential in sarcopenia, dystrophy, and cachexia research models. The growing body of published literature continues to expand our understanding of this compound's potential applications in laboratory settings.
Mechanism of Action
Trevogrumab is a fully human IgG4 monoclonal antibody that binds and neutralizes myostatin (GDF-8), a TGF-β superfamily member that negatively regulates skeletal myocyte differentiation. By blocking myostatin from binding its receptor ActRIIB, trevogrumab removes the endogenous brake on myocyte protein synthesis, enabling increased myofiber size and number. Preclinical and clinical studies have explored its potential in sarcopenia, dystrophy, and cachexia research models.
The signaling pathways activated by Trevogrumab (Regeneron) continue to be mapped through proteomic and transcriptomic analyses. Current research focuses on identifying the specific receptor subtypes and downstream effectors responsible for the observed biological responses. Understanding these molecular interactions is critical for advancing the compound from preclinical investigation toward potential translational applications.
Research Areas
- Growth hormone secretion pathway analysis
- Neurotrophic factor expression research
- Receptor binding kinetics
- Hormonal axis modulation
- Signal transduction research
Compound Specifications
| CAS Number | Proprietary (Regeneron REGN1033) |
| Purity | Recombinant, ≥95% SDS-PAGE |
| Storage | 2–8 °C. Do not freeze. Protect from light. |
| Category | Bioactive |
| Price | €195 |
| Format | Research reference, inquire |
Available Formats
- Research vial — contact for availability
Dissolution
Use our dilution calculator for precise concentration calculations.